{"url_path":"/sec/inbx/8-k/2026-07-16/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 Entry Into a Material Definitive Agreement","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/2007919/0002007919-26-000037-index.html","accession_number":"0002007919-26-000037","cik":"0002007919","ticker":"INBX","issuer_name":"Inhibrx Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2007919/0002007919-26-000037-index.html","primary_entity_key":"0002007919","primary_entity_name":"Inhibrx Biosciences, Inc."},"word_count":521,"has_tables":true,"body_markdown":"Item 1.01 Entry Into a Material Definitive Agreement\n\nOn July 15, 2026, Inhibrx Biosciences, Inc. (the “Company”), Oxford Finance LLC as collateral agent (“Collateral Agent”), and the other lenders party thereto (the “Lenders”), entered into a second amendment (the “Second Amendment”) to the Loan and Security Agreement dated as of January 13, 2025, as amended by the First Amendment dated March 18, 2026 (collectively, the “Oxford Loan Agreement”), pursuant to which the Lenders expanded the facility to an aggregate principal amount of up to $500.0 million (the “Credit Facility”).\n\nThe Second Amendment provides for an additional tranche, in an aggregate principal amount of $325.0 million in gross proceeds, (i) $100.0 million of which was funded upon execution of the Second Amendment (the “Term C Loan”) and (ii) up to an additional $225.0 million which may be funded in increments of $50.0 million or more upon the Company’s request and at the Lenders’ sole discretion (the “Term D Loan”).\n\nIn connection with the funding of the Term C Loan, the Company issued to the Lenders warrants (the “Term C Warrants”) to purchase 21,457 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at an exercise price of $93.21 per share. Upon the funding of the Term D Loan, the Company is required to issue to the Lenders additional warrants (the “Term D Warrants” and together with the Term C Warrants, the “Warrants”) to purchase such number of shares of the Common Stock to be equal to 2.0% of such additional funding divided by a price per share, which shall be the exercise price, equal to the lower of (i) the average closing price of the Common Stock on The Nasdaq Stock Market LLC (“Nasdaq”) for the ten consecutive trading days ending the day prior to such additional funding, and (ii) the closing price of the Common Stock on Nasdaq on the trading day immediately preceding such funding. The Warrants are immediately exercisable, and the exercise period will expire 10 years from the date of issuance.\n\nThe exercise price and the number of shares of Common Stock issuable upon exercise of the Warrants will be subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock.\n\nContemporaneously with the execution of the Second Amendment, the Company entered into a pledge agreement with the Collateral Agent, pledging any and all equity securities that the Company has in Poplar Therapeutics, Inc.\n\nExcept as noted above, the material terms of the Oxford Loan Agreement remain substantially unchanged.\n\nThe foregoing description of the Second Amendment and the Warrants contained herein does not purport to be complete and is qualified in its entirety by reference to the Second Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K, and the Form of Warrant to Purchase Stock, which was previously filed as Exhibit 4.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-42031), filed with the U.S. Securities and Exchange Commission on May 14, 2026, respectively, and in each case is incorporated herein by reference."}